44. Prevention and Treatment of Medical Complications

  1. Gary S. Hoffman MD, MS2,
  2. Cornelia M. Weyand MD, PhD3,
  3. Carol A. Langford MD, MHS2 and
  4. Jörg J. Goronzy MD, PhD3
  1. Atul Khasnis MD, MS1 and
  2. Carol A. Langford MD, MHS2

Published Online: 3 MAY 2012

DOI: 10.1002/9781118355244.ch44

Inflammatory Diseases of Blood Vessels, Second Edition

Inflammatory Diseases of Blood Vessels, Second Edition

How to Cite

Khasnis, A. and Langford, C. A. (2012) Prevention and Treatment of Medical Complications, in Inflammatory Diseases of Blood Vessels, Second Edition (eds G. S. Hoffman, C. M. Weyand, C. A. Langford and J. J. Goronzy), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118355244.ch44

Editor Information

  1. 2

    Department of Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH, USA

  2. 3

    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

Author Information

  1. 1

    Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA

  2. 2

    Department of Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH, USA

Publication History

  1. Published Online: 3 MAY 2012
  2. Published Print: 8 JUN 2012

ISBN Information

Print ISBN: 9781444338225

Online ISBN: 9781118355244

SEARCH

Keywords:

  • Vasculitis;
  • immunosuppression;
  • complications;
  • prevention;
  • infection;
  • malignancy

Summary

The immunosuppressive medications used in the treatment of vasculitis are associated with a wide range of complications. Both conventional and biologic agents increase the risk of infection through effects on host defense. Individual therapies have also been associated with malignancies, bone marrow suppression, metabolic effects and a potential impact on reproduction. As the toxicities of immunosuppressive therapy can be life-threatening, physician awareness and patient education are important. This chapter focuses on the general and agent-specific complications associated with the medications used to treat vasculitis patients and reviews strategies through which to monitor for and prevent their occurrence.